Treatment of indolent B-cell non-Hodgkin lymphomas (iNHL) of renal significance is challenging given the need for deep and prolonged hematological response to restore and control renal function overtime, yet to be balanced with the risk of adverse drug-related events. This prospective . One patient with a PHR had a renal relapse. Mortality rate was 10% at 12 months. The BR regimen was well tolerated overall. Thus, despite severe renal disease at presentation, a relapsing iNHL in 20% of patients and several comorbidities, the BR regimen was efficient and safe in our series. It should be further assessed as a first line therapy for patients with iNHL of renal significance.
Abstract
Treatment of indolent B-cell non-Hodgkin lymphomas (iNHL) of renal significance is challenging given the need for deep and prolonged hematological response to restore and control renal function overtime, yet to be balanced with the risk of adverse drug-related events. This prospective single-center study included 20 patients with iNHL of renal significance (tubulointerstitial presentation [n 5 8], glomerulopathy with or without monoclonal Ig deposits [n 5 12] ) who received a steroid-sparing regimen of rituximab plus bendamustine (BR), with either no or <1 month of steroid intake (as a first line therapy in 80%). Seventeen patients (85%) achieved a complete (CHR, n 5 12) or a partial (PHR, n 5 5) hematological response. Nine out of the 12 patients (75%) with iNHL-related glomerulopathy had a complete (CRR) or a partial (PRR) renal response. Among the six patients with glomerulopathy and CHR, five had a CRR (83%) compared to 1/6 (17%) that did not reach CHR. eGFR increased from 38 to 58 mL/min/1.73 m 2 , and returned to baseline in five patients. Among the eight patients with a tubulointerstitial presentation, six (75%) had a renal response (5 CRR), and eGFR increased from 29 to 48 mL/min/1.73 m 2 . One patient with a PHR had a renal relapse. Mortality rate was 10% at 12 months. The BR regimen was well tolerated overall. Thus, despite severe renal disease at presentation, a relapsing iNHL in 20% of patients and several comorbidities, the BR regimen was efficient and safe in our series. It should be further assessed as a first line therapy for patients with iNHL of renal significance.
| I N TR ODU C TI ON
Indolent non-Hodgkin's lymphomas (iNHL, i.e., Waldenstr€ om's macroglobulinemia or lymphoplasmacytic lymphoma [LPL] , chronic lymphocytic leukemia [CLL] , marginal zone lymphoma, indolent mantle-cell lymphoma) and B-cell monoclonal lymphocytosis are a group of monotypic B-cell disorders that can be accompanied by renal disease, including renal infiltration, deposition of an entire or a truncated monoclonal immunoglobulin, or renal autoimmune disorders not related to a circulating monoclonal Ig (mIg) but induced by overproduction of specific patterns of cytokines or unbalanced lymphocyte sub-populations. [1] [2] [3] [4] [5] [6] In patients with circulating monoclonal immunoglobulin and/or free light-chain, the glomerular lesions are heterogeneous 7, 8 and may include a membranous, membranoproliferative, diffuse proliferative, cryoglobulinemic, amyloid, or crescentic pattern. [9] [10] [11] Rare cases present with light-chain proximal tubulopathy. 12 Relapsing steroid-sensitive nephrotic syndrome linked to minimal-change disease or focal and segmental glomerulosclerosis is also associated with iNHL. 6 Recently, the International Kidney and Monoclonal Gammopathy
Research Group proposed a renal-pattern and clone-based recommendations to uniformly manage monoclonal gammopathy of renal significance.
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A rituximab-based combination was proposed in B-cell disorders but data from outcomes remain scarce or include patients with a heterogeneous therapeutic scheme. 14 Hence, to date, no treatment has emerged as a consensual first line therapy for patients with B-cell iNHL of renal significance.
Rituximab-cyclophosphamide-dexamethasone (RCD) is an efficient and safe combination that can target B-cell malignant clones and reverse autoimmune-related manifestations. [15] [16] [17] [18] reported that this combination led to a complete hematological and renal response in 63% of patients with iNHL and mIg-related glomerulonephritis. 19 In this cohort, 21% of patients developed a bacterial infection requiring hospitalization (a higher rate than previously reported with RCD in autoimmune cytopenia). 18 An alternative scheme remains to be tested with both improved hematological activity and overall safety, to be used as a frontline therapy or after relapse.
Bendamustine plus rituximab (BR) is a steroid-free regimen approved as a first line therapy in patients with CLL and others iNHL in US and Europe, 20 when chronic kidney injury precludes the use of fludarabine. In other B-cell lymphomas, there is no drug approval but BR is widely acknowledged as the best frontline option, especially in older patients with comorbidities. Bendamustine is a bifunctional drug that acts as an alkylating and antimetabolite agent with no or little renal clearance. 21 In patients with iNHL, the hematological response following BR reaches 80-90% (complete response 40%-60%). [22] [23] [24] [25] Unlike RCD, the lack of steroids with BR may be of interest to patients with diabetes mellitus, chronic kidney disease, or to reduce the risk of infection.
Herein, we report the outcomes of 20 patients with a B-cell iNHL of renal significance that all received a frontline or in relapse BR regimen. The aim of this study was to describe the renal and hematological responses, tolerance profiles, and long term renal outcomes.
| P A TI E NT S A ND M E TH ODS
In this prospective single-center study, we included all patients with a diag- . In patients that required hemodialysis, eGFR was arbitrarily set at 0.
| Renal and hematological response criteria
Hematological response was assessed according to the IWWM criteria for LPL and iwCLL criteria for CLL. 27, 28 A bone-marrow aspiration or a biopsy was not requested. A complete renal response was defined by a urinary protein/creatinine ratio <0.5 g/g, a lack of hematuria, and an increase in eGFR to >15 mL/min/1.73 m 2 in patients with a baseline eGFR of <60 mL/min/1.73 m 2 . A partial renal response was defined as stable or an improved eGFR, associated with a decrease in proteinuria that was >50%.
| Statistical analyses
Continuous variables are reported as their median and interquartile ranges (IQR). Statistical analyses were performed using GraphPad Prism6 software (San Diego, CA, USA). Univariate analyses were performed using the Mann-Whitney-Wilcoxon or the one-way ANOVA test, as appropriate for each variable type. Statistical significance was assumed at P < .05. 
| RE S U L TS

| Renal presentations and pathologic findings
Twelve patients had a glomerular disease, whereas eight had tubulointerstitial nephropathy. Among the patients with a glomerular presentation, the urinary protein/creatinine ratio was 4.7 g/g [2. observed. In patients with mIg-related glomerulopathy, the Ig deposits were restricted to the IgM isotype in five patients and to IgG in one.
Three patients had AL amyloidosis (k, n 5 3) and one had AL/AH IgMk amyloidosis). Severe interstitial fibrosis (i.e., >20% of interstitial area) was observed in one renal biopsy, whereas <10% interstitial fibrosis was observed in the other patients.
Among the patients with a tubulo-interstitial presentation, proteinuria was null in all individuals except for four that had a urinary protein/creatinine ratio of between 0.5 and 1 g/g: two had hematuria and 
| Hematological malignancy and immunological findings
| Tolerance
During the follow-up period, three patients died (at 7, 9, and 20 months after initiating treatment). The causes of death were refractory patients, respectively. Importantly, no patient developed febrile neutropenia, and 3 required red blood cells transfusion (erythropoietin was given in 10 patients).
At the last follow-up, one patient developed a histologic transformation of CLL into Hodgkin's disease, not related to the BR regimen but rather to clonal evolution.
| D I SCUSSION
Renal involvement of B-cell iNHL includes a broad spectrum of glomerular, tubulo-interstitial, or mixed diseases. 1, 6 Renal presentations are heterogeneous, thus confirming the need for an accurate pathological diagnosis in patients with iNHL and renal failure or active urinary sediment. 1 Likewise, an in-depth search for and the characterization of hematological malignancies should be proposed for all patients with a renal pathology suggestive of an underlying B-cell iNHL. In our study, five patients had a monoclonal B-cell lymphocytosis (i.e., a circulating In our series, CLL and LPL were the main diagnoses. Tubulointerstitial presentation was more frequently associated with CLL. We confirm that LPL-related glomerulopathy was heterogeneous, and that AL or AH/AL amyloidosis, membranoproliferative glomerulonephritis, and minimal-change disease can also be encountered. 29 BR regimen yielded an encouraging hematological response rate of 85% of our cases, including 60% complete response rates. Of note, two of the four patients that previously received chemotherapy achieved a complete hematological response. A renal response was obtained in 75% of patients. Of importance, 4/5 patients without a renal response had no hematological response and the fifth had only a partial hematological response. Three of these five patients had AL or AL/AH amyloidosis, a nephropathy characterized by its inconstant renal response to therapy. 30 Our findings confirm that a complete hematological response is the main predictor for a prolonged renal response, but also that an early response is desirable.
In previous reports of outcomes of CLL and LPL patients after BR therapy, the hematological response rates reached 40-75% (complete response: 7-40%). 21, 22, 24, 25, [31] [32] [33] In patients with CLL and autoimmune hemolytic anemia, BR led to an overall response of 81% for autoimmune hemolytic anemia and 77% for CLL. 34 Despite a controlled, randomized trial has never been published, these rates compare favorably with RCD in the same population of patients (some RCDrefractory patients even received BR as salvage). Similarly BR seemed to yield very promising results in an hard-to-treat rare hemolysis (cold agglutinin disease 35 ). These findings are very similar to our own data, and highlight that BR regimen can be valuable for patients with CLL and renal immune complications as well. However, hematological response rates of LPL (complete and partial response in 14% and 57%, respectively) were somewhat disappointing in our series. These results agree with those obtained in previous cohorts of patients with de novo or relapsing LPL, in which BR led to a 70 to 75% hematological response, but only to a 7 to 40% complete response. 36, 37 In this subtype of B-cell lymphoma, whether combined rituximab-cyclophosphamide-dexamethasone therapy should be preferably given to patients with proliferative glomerulonephritis (i.e., at risk of rapid renal progression) 19 should be addressed in a larger cohort. Indeed, for patients with hematological malignancies and related renal diseases, the choice of treatment should be based on both the awaited hematological response but also the characteristics of the nephropathy, which may need an urgent renal response. In the longer term, BR regimen was followed by a hematological or renal relapse in only one patient in our study, confirming prolonged hematological response 36 was associated with a better long-term renal prognosis. To that aim, recently approved drugs for CLL, MCL and LPL such as ibrutinib (frontline or relapse setting) represent therapeutic hopes in a near future. Of note, in previous reports, no patient reached complete hematological response after ibrutinib in LPL patients thus limiting its use as frontline therapy.
In a retrospective cohort including 775 CLL patients (57% aged >70 years) treated with bendamustine alone or with rituximab, the 3-year overall survival rate was 72%. 38 In our series, despite the short follow-up, survival rate seemed similar (85% at 16 months). In our study, two patients died during the first 12 months of follow-up because of refractory systemic amyloidosis or the development of a second hematological malignancy (Hodgkin's lymphoma). The third death occurred from refractory amyloidosis complicating lymphoma relapse. Hence, the safety profile of BR given to our patients with Bcell iNHL of renal significance was very good, despite their median age was 71 years, with sometimes severe renal failure at presentation. A prophylaxis with valacyclovir, trimethoprim-sulfamethoxazole, and probably amoxicillin should be proposed to all patients receiving BR regimen to minimize the risk of opportunistic and bacterial infections.
In patients with systemic amyloidosis, rapid hematological response is necessary for organ response and subsequent improvement of the outcome. In iNHL-related amyloidosis, no comparative prospective study has been performed preventing optimal management. Here, we followed the recommendations of the French referral center for amyloidosis and used BR with immunological assessment after 3 cycles. In the two patients that died from refractory amyloidosis, the LLP was refractory to
Melphalan-Dexamethasone (n 5 1), BR (n 5 2), and ibrutinib (n 5 2) regimen. Whether Rituximab-Cyclophosphamide-Dexamethasone is superior to BR in the subgroup of patients with LLP-related amyloidosis remains to be determined.
A limitation of this prospective observational study was the absence of electron-microscopy data, which prevented exact classification of the pathological changes. However, to date, although histological subtypes can modify the renal response (for instance, in cases of amyloidosis), the choice of treatment is mostly guided by the characteristics of the hematological malignancy and the need for a rapid, dramatic, and prolonged hematological response. 14 Nonetheless, in-depth characterization of the renal pathology should be obtained to better address the renal prognosis. 39 In conclusion, we report here that BR regimen provided very encouraging and durable hematological and renal responses in patients with B-cell iNHL of renal significance. Further studies will need to address which subgroup of patients could benefit most from BR or RCD, especially in the management of frontline setting.
DISCLOSURE
The authors have no competing financial interests. 
AUTHOR CONTRIBUTIONS
